30 results on '"Cowie, Benjamin"'
Search Results
2. Evaluating a novel model of hepatitis B care, Hep B PAST, in the Northern Territory of Australia: results from a prospective, population-based study
- Author
-
Hosking, Kelly, Binks, Paula, De Santis, Teresa, Wilson, Phillip Merrdi, Gurruwiwi, George Garambaka, Bukulatjpi, Sarah Mariyalawuy, Vintour-Cesar, Emily, McKinnon, Melita, Nihill, Peter, Fernandes, Tammy-Allyn, Greenwood-Smith, Belinda, Batey, Robert, Ross, Cheryl, Tong, Steven Y.C., Stewart, Geoffrey, Marshall, Catherine, Gargan, Catherine, Manchikanti, Prashanti, Fuller, Karen, Tate-Baker, Jaclyn, Stewart, Sami, Cowie, Benjamin, Allard, Nicole, MacLachlan, Jennifer H., Qama, Ashleigh, Boettiger, David, Davis, Joshua S., Connors, Christine, and Davies, Jane
- Published
- 2024
- Full Text
- View/download PDF
3. Vaccination coverage among people who inject drugs: A systematic review
- Author
-
Price, Olivia, Swanton, Rosie, Grebely, Jason, Hajarizadeh, Behzad, Webb, Paige, Peacock, Amy, Dore, Gregory J., Cowie, Benjamin C., Vickerman, Peter, and Degenhardt, Louisa
- Published
- 2024
- Full Text
- View/download PDF
4. Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study
- Author
-
Van Heer, Christina, Majumdar, Suman S., Parta, Indra, Martinie, Marcellin, Dawson, Rebecca, West, Daniel, Hewett, Laura, Lister, David, Sutton, Brett, O’Brien, Daniel P., and Cowie, Benjamin C.
- Published
- 2023
- Full Text
- View/download PDF
5. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
- Author
-
Razavi-Shearer, Devin, Gamkrelidze, Ivane, Pan, Calvin, Jia, Jidong, Berg, Thomas, Gray, Richard, Lim, Young-Suk, Chen, Chien-Jen, Ocama, Ponsiano, Desalegn, Hailemichael, Abbas, Zaigham, Abdallah, Ayat, Aghemo, Alessio, Ahmadbekova, Sabohat, Ahn, Sang Hoon, Aho, Inka, Akarca, Ulus, Al Masri, Nasser, Alalwan, Abduljaleel, Alavian, Seyed, Al-Busafi, Said, Aleman, Soo, Alfaleh, Faleh, Alghamdi, Abdullah, Al-Hamoudi, Waleed, Aljumah, Abdulrahman, Al-Naamani, Khalid, Al-Rifai, Ahmad, Alserkal, Yousif, Altraif, Ibrahim, Amarsanaa, Jazag, Anderson, Motswedi, Andersson, Monique, Armstrong, Paige, Asselah, Tarik, Athanasakis, Kostas, Baatarkhuu, Oidov, Ben-Ari, Ziv, Bensalem, Aicha, Bessone, Fernando, Biondi, Mia, Bizri, Abdul Rahman, Blach, Sarah, Braga, Wornei, Brandão-Mello, Carlos, Brosgart, Carol, Brown, Kimberly, Brown, Jr, Robert, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Cabezas, Joaquin, Casanovas, Teresa, Chae, Chungman, Chan, Henry Lik Yuen, Cheinquer, Hugo, Chen, Pei-Jer, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Coffin, Carla, Contreras, Fernando, Coppola, Nicola, Cornberg, Markus, Cowie, Benjamin, Cramp, Matthew, Craxi, Antonio, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris, Dalgard, Olav, De Knegt, Robert, De Ledinghen, Victor, Dore, Gregory, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve, Elbadri, Mohammed, El-Kassas, Mohamed, El-Sayed, Manal, Estes, Chris, Etzion, Ohad, Farag, Elmobashar, Ferradini, Laurent, Ferreira, Paulo, Flisiak, Robert, Forns, Xavier, Frankova, Sona, Fung, James, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana, Gholam, Pierre, Gish, Robert, Goleij, Pouya, Gottfredsson, Magnus, Grebely, Jason, Gschwantler, Michael, Guingane, Nanelin Alice, Hajarizadeh, Behzad, Hamid, Saeed, Hamoudi, Waseem, Harris, Aaron, Hasan, Irsan, Hatzakis, Angelos, Hellard, Margaret, Hercun, Julian, Hernandez, Javier, Hockicková, Ivana, Hsu, Yao-Chun, Hu, Ching-Chih, Husa, Petr, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jelev, Deian, Jeruma, Agita, Johannessen, Asgeir, Kåberg, Martin, Kaita, Kelly, Kaliaskarova, Kulpash, Kao, Jia-Horng, Kelly-Hanku, Angela, Khamis, Faryal, Khan, Aamir, Kheir, Omer, Khoudri, Ibtissam, Kondili, Loreta, Konysbekova, Aliya, Kristian, Pavol, Kwon, Jisoo, Lagging, Martin, Laleman, Wim, Lampertico, Pietro, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice, Lee, Mei-Hsuan, Liakina, Valentina, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham, Marinho, Rui, Mendes-Correa, Maria Cássia, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mohamed, Rosmawati, Mokhbat, Jacques, Mooneyhan, Ellen, Moreno, Christophe, Mortgat, Laure, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Naveira, Marcelo, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Ning, Qing, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin, Oguche, Stephen, Omuemu, Casimir, Ong, Janus, Opare-Sem, Ohene, Örmeci, Necati, Orrego, Mauricio, Osiowy, Carla, Papatheodoridis, George, Peck-Radosavljevic, Markus, Pessoa, Mário, Pham, Trang, Phillips, Richard, Pimenov, Nikolay, Pincay-Rodríguez, Loreley, Plaseska-Karanfilska, Dijana, Pop, Cora, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Rautiainen, Henna, Razavi-Shearer, Kathryn, Remak, William, Ribeiro, Sofia, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo, Robalino, Marcia, Roberts, Lewis, Roberts, Stuart, Rodríguez, Manuel, Roulot, Dominique, Rwegasha, John, Ryder, Stephen, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa, Salupere, Riina, Sanai, Faisal, Sanchez-Avila, Juan F, Saraswat, Vivek, Sargsyants, Narina, Sarrazin, Christoph, Sarybayeva, Gulya, Schréter, Ivan, Seguin-Devaux, Carole, Seto, Wai-Kay, Shah, Samir, Sharara, Ala, Sheikh, Mahdi, Shouval, Daniel, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta, Sinn, Dong Hyun, Sonderup, Mark, Sonneveld, Milan, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek-Siam, Tanaka, Junko, Tergast, Tammo, Terrault, Norah, Thompson, Alexander, Thompson, Peyton, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsang, Tak-Yin, Uzochukwu, Benjamin, Van Welzen, Berend, Vanwolleghem, Thomas, Vince, Adriana, Voeller, Alexis, Waheed, Yasir, Waked, Imam, Wallace, Jack, Wang, Cong, Weis, Nina, Wong, Grace, Wong, Vincent, Wu, Jaw-Ching, Yaghi, Cesar, Yesmembetov, Kakharman, Yip, Terry, Yosry, Ayman, Yu, Ming-Lung, Yuen, Man-Fung, Yurdaydin, Cihan, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie
- Published
- 2023
- Full Text
- View/download PDF
6. Excess mortality among people with communicable diseases over a 30-year period, Victoria, Australia: a whole of population cohort study
- Author
-
Rowe, Stacey L., Leder, Karin, Sundaresan, Lalitha, Wollersheim, Dennis, Lawrie, Jock, Stephens, Nicola, Cowie, Benjamin C., Nolan, Terry M., and Cheng, Allen C.
- Published
- 2023
- Full Text
- View/download PDF
7. Progress towards triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Pacific Island Countries and Territories: a systematic review
- Author
-
Bell, Leila, van Gemert, Caroline, Allard, Nicole, Brink, Anne, Chan, Po-Lin, Cowie, Benjamin, Hellard, Margaret, Homer, Caroline S.E., Howell, Jess, O'Connor, Michelle, and Hocking, Jane
- Published
- 2023
- Full Text
- View/download PDF
8. Modelling jurisdictional disparities in the cascade of care for chronic hepatitis B in Australia: impact of treatment uptake on mortality
- Author
-
McCulloch, Karen, Romero, Nicole, Allard, Nicole, MacLachlan, Jennifer H., and Cowie, Benjamin C.
- Published
- 2023
- Full Text
- View/download PDF
9. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- Author
-
Sheena, Brittney S, Hiebert, Lindsey, Han, Hannah, Ippolito, Helen, Abbasi-Kangevari, Mohsen, Abbasi-Kangevari, Zeinab, Abbastabar, Hedayat, Abdoli, Amir, Abubaker Ali, Hiwa, Adane, Mesafint Molla, Adegboye, Oyelola A, Adnani, Qorinah Estiningtyas Sakilah, Advani, Shailesh M, Afzal, Muhammad Sohail, Afzal, Saira, Aghaie Meybodi, Mohamad, Ahadinezhad, Bahman, Ahinkorah, Bright Opoku, Ahmad, Sajjad, Ahmad, Tauseef, Ahmadi, Sepideh, Ahmed, Haroon, Ahmed, Muktar Beshir, Ahmed Rashid, Tarik, Akalu, Gizachew Taddesse, Aklilu, Addis, Akram, Tayyaba, Al Hamad, Hanadi, Alahdab, Fares, Alem, Adugnaw Zeleke, Alem, Dejene Tsegaye, Alhalaiqa, Fadwa Alhalaiqa Naji, Alhassan, Robert Kaba, Ali, Liaqat, Ali, Muhammad Ashar, Alimohamadi, Yousef, Alipour, Vahid, Alkhayyat, Motasem, Almustanyir, Sami, Al-Raddadi, Rajaa M, Altawalah, Haya, Amini, Saeed, Amu, Hubert, Ancuceanu, Robert, Andrei, Catalina Liliana, Andrei, Tudorel, Anoushiravani, Amir, Ansar, Adnan, Anyasodor, Anayochukwu Edward, Arabloo, Jalal, Arab-Zozani, Morteza, Argaw, Ayele Mamo, Argaw, Zeleke Gebru, Arshad, Muhammad, Artamonov, Anton A, Ashraf, Tahira, Atlaw, Daniel, Ausloos, Floriane, Ausloos, Marcel, Azadnajafabad, Sina, Azangou-Khyavy, Mohammadreza, Azari Jafari, Amirhossein, Azarian, Ghasem, Bagheri, Sayna, Bahadory, Saeed, Baig, Atif Amin, Banach, Maciej, Barati, Nastaran, Barrow, Amadou, Batiha, Abdul-Monim Mohammad, Bejarano Ramirez, Diana Fernanda, Belgaumi, Uzma Iqbal, Berhie, Alemshet Yirga, Bhagat, Devidas S, Bhardwaj, Nikha, Bhardwaj, Pankaj, Bhattacharyya, Krittika, Bhojaraja, Vijayalakshmi S, Bijani, Ali, Biondi, Antonio, Bodicha, Belay Boda Abule, Bojia, Hunduma Amensisa, Boloor, Archith, Bosetti, Cristina, Braithwaite, Dejana, Briko, Nikolay Ivanovich, Butt, Zahid A, Cámera, Luis Alberto, Chakinala, Raja Chandra, Chakraborty, Promit Ananyo, Charan, Jaykaran, Chen, Shu, Choi, Jee-Young Jasmine, Choudhari, Sonali Gajanan, Chowdhury, Fazle Rabbi, Chu, Dinh-Toi, Chung, Sheng-Chia, Cortesi, Paolo Angelo, Cowie, Benjamin C, Culbreth, Garland T, Dadras, Omid, Dai, Xiaochen, Dandona, Lalit, Dandona, Rakhi, De la Hoz, Fernando Pio, Debela, Sisay Abebe, Dedefo, Mohammed Gebre, Demeke, Feleke Mekonnen, Demie, Takele Gezahegn G, Demissie, Getu Debalkie, Derbew Molla, Meseret, Desta, Abebaw Alemayehu, Dhamnetiya, Deepak, Dhimal, Mandira Lamichhane, Dhimal, Meghnath, Didehdar, Mojtaba, Doan, Linh Phuong, Dorostkar, Fariba, Drake, Thomas M, Eghbalian, Fatemeh, Ekholuenetale, Michael, El Sayed, Iman, El Sayed Zaki, Maysaa, Elhadi, Muhammed, Elmonem, Mohamed A, Elsharkawy, Aisha, Enany, Shymaa, Enyew, Daniel Berhanie, Erkhembayar, Ryenchindorj, Eskandarieh, Sharareh, Esmaeilzadeh, Firooz, Ezzikouri, Sayeh, Farrokhpour, Hossein, Fetensa, Getahun, Fischer, Florian, Foroutan, Masoud, Gad, Mohamed M, Gaidhane, Abhay Motiramji, Gaidhane, Shilpa, Galles, Natalie C, Gallus, Silvano, Gebremeskel, Teferi Gebru, Gebreyohannes, Eyob Alemayehu, Ghadiri, Keyghobad, Ghaffari, Kazem, Ghafourifard, Mansour, Ghamari, Seyyed-Hadi, Ghashghaee, Ahmad, Gholami, Ali, Gholizadeh, Abdolmajid, Gilani, Aima, Goel, Amit, Golechha, Mahaveer, Goleij, Pouya, Golinelli, Davide, Gorini, Giuseppe, Goshu, Yitayal Ayalew, Griswold, Max G, Gubari, Mohammed Ibrahim Mohialdeen, Gupta, Bhawna, Gupta, Sapna, Gupta, Veer Bala, Gupta, Vivek Kumar, Haddadi, Rasool, Halwani, Rabih, Hamid, Saeed S, Hamidi, Samer, Hanif, Asif, Haque, Shafiul, Harapan, Harapan, Hargono, Arief, Hariri, Sanam, Hasaballah, Ahmed I, Hasan, S M Mahmudul, Hassanipour, Soheil, Hassankhani, Hadi, Hay, Simon I, Hayat, Khezar, Heidari, Golnaz, Herteliu, Claudiu, Heyi, Demisu Zenbaba, Hezam, Kamal, Holla, Ramesh, Hosseini, Mohammad-Salar, Hosseini, Mostafa, Hosseinzadeh, Mehdi, Hostiuc, Mihaela, Househ, Mowafa, Huang, Junjie, Hussein, Nawfal R, Iavicoli, Ivo, Ibitoye, Segun Emmanuel, Ilesanmi, Olayinka Stephen, Ilic, Irena M, Ilic, Milena D, Irham, Lalu Muhammad, Islam, Jessica Y, Ismail, Nahlah Elkudssiah, Jacobsen, Kathryn H, Jadidi-Niaragh, Farhad, Javadi Mamaghani, Amirreza, Jayaram, Shubha, Jayawardena, Ranil, Jebai, Rime, Jha, Ravi Prakash, Joseph, Nitin, Joukar, Farahnaz, Kaambwa, Billingsley, Kabir, Ali, Kabir, Zubair, Kalhor, Rohollah, Kandel, Himal, Kanko, Tesfaye K Tesfaye, Kantar, Rami S, Karaye, Ibraheem M, Kassa, Bekalu Getnet, Kemp Bohan, Phillip M, Keykhaei, Mohammad, Khader, Yousef Saleh, Khajuria, Himanshu, Khan, Gulfaraz, Khan, Imteyaz A, Khan, Junaid, Khan, Moien AB, Khanali, Javad, Khater, Amir M, Khatib, Mahalaqua Nazli, Khodadost, Mahmoud, Khoja, Abdullah T, Khosravizadeh, Omid, Khubchandani, Jagdish, Kim, Gyu Ri, Kim, Hanna, Kim, Min Seo, Kim, Yun Jin, Kocarnik, Jonathan M, Kolahi, Ali-Asghar, Koteeswaran, Rajasekaran, Kumar, G Anil, La Vecchia, Carlo, Lal, Dharmesh Kumar, Landires, Iván, Lasrado, Savita, Lazarus, Jeffrey V, Ledda, Caterina, Lee, Doo Woong, Lee, Sang-woong, Lee, Yeong Yeh, Levi, Miriam, Li, Jiarui, Lim, Stephen S, Lobo, Stany W, Lopukhov, Platon D, Loureiro, Joana A, MacLachlan, Jennifer H, Magdy Abd El Razek, Hassan, Magdy Abd El Razek, Muhammed, Majeed, Azeem, Makki, Alaa, Malekpour, Mohammad-Reza, Malekzadeh, Reza, Malik, Ahmad Azam, Mansour-Ghanaei, Fariborz, Mansournia, Mohammad Ali, Martins-Melo, Francisco Rogerlândio, Matthews, Philippa C, Mendoza, Walter, Menezes, Ritesh G, Meretoja, Tuomo J, Mersha, Amanual Getnet, Mestrovic, Tomislav, Miller, Ted R, Minh, Le Huu Nhat, Mirica, Andreea, Mirmoeeni, Seyyedmohammadsadeq, Mirrakhimov, Erkin M, Misra, Sanjeev, Mithra, Prasanna, Moazen, Babak, Mohamadkhani, Ashraf, Mohammadi, Mokhtar, Mohammed, Shafiu, Moka, Nagabhishek, Mokdad, Ali H, Moludi, Jalal, Momtazmanesh, Sara, Monasta, Lorenzo, Moradi, Ghobad, Moradzadeh, Maliheh, Moradzadeh, Rahmatollah, Moraga, Paula, Mostafavi, Ebrahim, Mubarik, Sumaira, Muniyandi, Malaisamy, Murray, Christopher J L, Naghavi, Mohsen, Naimzada, Mukhammad David, Narasimha Swamy, Sreenivas, Natto, Zuhair S, Nayak, Biswa Prakash, Nazari, Javad, Negoi, Ionut, Negru, Serban Mircea, Nejadghaderi, Seyed Aria, Neupane Kandel, Sandhya, Nguyen, Huong Lan Thi, Ngwa, Che Henry, Niazi, Robina Khan, Nnaji, Chukwudi A, Noubiap, Jean Jacques, Nowroozi, Ali, Nuñez-Samudio, Virginia, Oancea, Bogdan, Ochir, Chimedsuren, Odukoya, Oluwakemi Ololade, Oh, In-Hwan, Olagunju, Andrew T, Olakunde, Babayemi Oluwaseun, Omar Bali, Ahmed, Omer, Emad, Otstavnov, Stanislav S, Oumer, Bilcha, Padubidri, Jagadish Rao, Pana, Adrian, Pandey, Anamika, Park, Eun-Cheol, Pashazadeh Kan, Fatemeh, Patel, Urvish K, Paudel, Uttam, Petcu, Ionela-Roxana, Piracha, Zahra Zahid, Pollok, Richard Charles G, Postma, Maarten J, Pourshams, Akram, Poustchi, Hossein, Rabiee, Mohammad, Rabiee, Navid, Rafiei, Alireza, Rafiei, Sima, Raghuram, Pavan Manibettu, Rahman, Mosiur, Rahmani, Amir Masoud, Rahmawaty, Setyaningrum, Rajesh, Aashish, Ranasinghe, Priyanga, Rao, Chythra R, Rao, Sowmya J, Rashidi, Mahsa, Rashidi, Mohammad-Mahdi, Rawaf, David Laith, Rawaf, Salman, Rawassizadeh, Reza, Rezaei, Negar, Rezapour, Aziz, Rezazadeh-Khadem, Sahba, Rodriguez, Jefferson Antonio Buendia, Rwegerera, Godfrey M, Sabour, Siamak, Saddik, Basema, Saeb, Mohammad Reza, Saeed, Umar, Sahebkar, Amirhossein, Saif-Ur-Rahman, KM, Salahi, Sarvenaz, Salimzadeh, Hamideh, Sampath, Chethan, Samy, Abdallah M, Sanabria, Juan, Sanmarchi, Francesco, Santric-Milicevic, Milena M, Sarveazad, Arash, Sathian, Brijesh, Sawhney, Monika, Seidu, Abdul-Aziz, Sepanlou, Sadaf G, Seylani, Allen, Shahabi, Saeed, Shaikh, Masood Ali, Shaker, Elaheh, Shakhmardanov, Murad Ziyaudinovich, Shannawaz, Mohammed, Shenoy, Suchitra M, Shetty, Jeevan K, Shetty, Pavanchand H, Shibuya, Kenji, Shin, Jae Il, Shobeiri, Parnian, Sibhat, Migbar Mekonnen, Singh, Achintya Dinesh, Singh, Jasvinder A, Singh, Surjit, Skryabin, Valentin Yurievich, Skryabina, Anna Aleksandrovna, Sohrabpour, Amir Ali, Song, Suhang, Tabaeian, Seidamir Pasha, Tadesse, Eyayou Girma, Taheri, Majid, Tampa, Mircea, Tan, Ker-Kan, Tavakoli, Ahmad, Tbakhi, Abdelghani, Tefera, Belay Negash, Tehrani-Banihashemi, Arash, Tesfaw, Habtamu Molla, Thapar, Rekha, Thavamani, Aravind, Tohidast, Seyed Abolfazl, Tollosa, Daniel Nigusse, Tosti, Maria Elena, Tovani-Palone, Marcos Roberto, Traini, Eugenio, Tran, Mai Thi Ngoc, Trihandini, Indang, Tusa, Biruk Shalmeno, Ullah, Irfan, Vacante, Marco, Valadan Tahbaz, Sahel, Valdez, Pascual R, Varthya, Shoban Babu, Vo, Bay, Waheed, Yasir, Weldesenbet, Adisu Birhanu, Woldemariam, Melat, Xu, Suowen, Yahyazadeh Jabbari, Seyed Hossein, Yaseri, Mehdi, Yeshaw, Yigizie, Yiğit, Vahit, Yirdaw, Birhanu Wubale, Yonemoto, Naohiro, Yu, Chuanhua, Yunusa, Ismaeel, Zahir, Mazyar, Zaki, Leila, Zamani, Mohammad, Zamanian, Maryam, Zastrozhin, Mikhail Sergeevich, Vos, Theo, Ward, John W, and Dirac, M Ashworth
- Published
- 2022
- Full Text
- View/download PDF
10. A pilot project harnessing surveillance systems to support clinicians providing clinical care for people diagnosed with hepatitis C in Victoria, Australia, September 2021 to 31 March 2022.
- Author
-
Abbott, Mielle, MacLachlan, Jennifer H., Romero, Nicole, Matthews, Nicole, Higgins, Nasra, Lee, Alvin, Stoove, Mark, Marukutira, Tafireyi, Quinn, Brendan, Allard, Nicole L., and Cowie, Benjamin C.
- Published
- 2024
- Full Text
- View/download PDF
11. The cascade of care for hepatitis C in Victoria, Australia: a data linkage cohort study.
- Author
-
Snow, Kathryn, MacLachlan, Jennifer H., Rowe, Stacey, Higgins, Nasra, and Cowie, Benjamin C.
- Subjects
RESEARCH funding ,HEPATITIS viruses ,MEDICAL care ,PATIENT care ,CONTINUUM of care ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,LONGITUDINAL method ,ANTIVIRAL agents ,MEDICAL records ,ACQUISITION of data ,VIREMIA ,INFORMATION retrieval ,HEPATITIS C ,CONFIDENCE intervals - Abstract
Background: Highly effective hepatitis C therapies are available in Australia. However, people living with hepatitis C face various barriers to accessing care and treatment. Aims: To identify gaps in the cascade of care for hepatitis C and generate estimates of the number living with untreated infection according to population group, using a representative longitudinal study population. Methods: We linked hepatitis C notification data from Victoria to national pathology, prescribing and death registry data. We assessed receipt of key clinical services in a large cohort who tested positive for hepatitis C from 1 January 2000 to 31 December 2016, with follow‐up to 30 June 2018. We estimated the number still living with hepatitis C, adjusting for spontaneous clearance and mortality. Results: The cohort comprised 45 391 people positive for hepatitis C. Of these, 13 346 (29%) received treatment and an estimated 28% (95% confidence interval (CI): 26–30%) were still living with chronic infection at 30 June 2018, with the remainder still living following spontaneous clearance (30%, 95% CI: 29–32%) or having died (12%, 95% CI: 12–12%). Half (50%) of those still living with hepatitis C were born from 1965 to 1980, and 74% first tested positive before 2011. Conclusions: Despite an enabling policy environment and subsidised therapy, many people in this cohort were not treated. Increased measures may be needed to engage people in care, including those who acquired hepatitis C more than 10 years ago. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Access to oral COVID‐19 antivirals in the community: are eligibility criteria and systems ensuring equity?
- Author
-
Allard, Nicole L, Canevari, Jose, Haslett, Nick, and Cowie, Benjamin C
- Abstract
COVID-19 mortality and morbidity data should include information on vaccination status, and both eligibility and receipt of COVID-19 oral antivirals. Access to oral COVID-19 antivirals in the community: are eligibility criteria and systems ensuring equity? Keywords: COVID-19; Public health EN COVID-19 Public health 438 441 4 06/06/23 20230601 NES 230601 With substantial SARS-CoV-2 transmission in the community, early oral antiviral access has become a pillar of our response Oral antiviral therapies for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) are recommended in Australian guidelines to reduce the risk of serious illness, hospitalisation and mortality in people who do not require oxygen and have risk factors for progression to severe disease.[1] Oral treatments should be started within five days after onset of symptoms, or as soon as practical after diagnosis in an asymptomatic individual.[1] With substantial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in the community and great health system pressures and excess mortality nationwide due to COVID-19 (most of which has been experienced in 2022), early oral antiviral access has become a pillar of our response. Integrating general practice into the Australian COVID-19 response: a description of the General Practitioner Respiratory Clinic Program in Australia. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
13. Mapping the delivery of interventions for vaccine-preventable infections in pregnancy in Victoria, Australia.
- Author
-
Yussf, Nafisa, Allard, Nicole, Romero, Nicole, Wilson, Ann, Wallace, Jack, Perrier, Meg, Rowe, Stacey, Morey, Rosemary, Aykut, Neylan, and Cowie, Benjamin
- Subjects
INFLUENZA prevention ,HEPATITIS B prevention ,PREVENTION of communicable diseases ,MATERNAL health services ,VACCINES ,MEDICAL care ,MEDICAL screening ,SURVEYS ,WHOOPING cough ,QUESTIONNAIRES ,HEALTH equity ,PREGNANCY - Abstract
Background: Standard care for pregnant women includes universal screening for hepatitis B, and administration of influenza and pertussis vaccination to women and hepatitis B infant vaccination. This study explored how perinatal services relating to the prevention of these vaccine-preventable diseases are delivered to women and their infants in Victoria, Australia. Methods: Two online surveys investigated service delivery for the prevention of influenza, pertussis and hepatitis B to identify barriers to optimal care during January–June 2021; (1) The Birthing Hospitals Survey captured facility-level information about service delivery for influenza and pertussis vaccination, and interventions to prevent mother-to-child-transmission of chronic hepatitis B (CHB); and (2) The Healthcare Providers Survey captured individual staff perceptions and knowledge in community and hospital settings. Results: Thirty-four hospital unit managers (61%) completed The Birthing Hospitals Survey. One-hundred and forty participants completed The Healthcare Providers Survey. Half of the birthing hospitals provided influenza (50%) and pertussis (53%) vaccinations to pregnant women, and 53% provided an infectious diseases service for women with CHB. Barriers to optimal care delivery included reliance on pregnant woman's self-report to confirm influenza, pertussis vaccination and CHB status, lack of standardised reporting, inadequate workforce training, poor communication between services, and lack of guideline-based clinical care for mothers with CHB and their infants. Three hospitals reported 'stock out' of hepatitis B immunoglobulin (HBIG). Conclusion: Coordinated and standardised system and clinical care improvements are required to provide equitable care for pregnant women and their infants, including training and education for healthcare providers, improving data capture and communication among health services. This study used data from two online surveys to understand how perinatal services relating to the prevention of vaccine-preventable diseases (influenza, pertussis and chronic hepatitis B) are delivered to pregnant women and their infants in Victoria, Australia. It provides knowledge and insights into system-level service delivery gaps for pregnant women and their infants. Coordinated and standardised care delivery improvements are required to reduce the burden of vaccine-preventable infections during pregnancy and in early infancy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma.
- Author
-
Mnatzaganian, George, MacLachlan, Jennifer H, Allard, Nicole, Brown, Chelsea, Rowe, Stacey, and Cowie, Benjamin C
- Subjects
HEPATITIS B ,DIAGNOSTIC errors ,HEPATOCELLULAR carcinoma ,VIRAL hepatitis ,GENERAL practitioners ,CHRONIC hepatitis B ,HEPATITIS C - Abstract
Background and Aim: This study aimed to assess utilization of health‐care services in people with decompensated cirrhosis (DC) or hepatocellular carcinoma (HCC) and a "late diagnosis" of hepatitis B or hepatitis C. Methods: Hepatitis B and C cases during 1997–2016 in Victoria, Australia, were linked with hospitalizations, deaths, liver cancer diagnoses, and medical services. A late diagnosis was defined as hepatitis B or hepatitis C notification occurring after, at the same time, or within 2 years preceding an HCC/DC diagnosis. Services provided during the 10‐year period before HCC/DC diagnosis were assessed, including general practitioner (GP) or specialist visits, emergency department presentations, hospital admissions, and blood tests. Results: Of the 25 766 notified cases of hepatitis B, 751 (2.9%) were diagnosed with HCC/DC, and hepatitis B was diagnosed late in 385 (51.3%). Of 44 317 cases of hepatitis C, 2576 (5.8%) were diagnosed with HCC/DC, and hepatitis C was diagnosed late in 857 (33.3%). Although late diagnosis dropped over time, missed opportunities for timely diagnosis were observed. Most people diagnosed late had visited a GP (97.4% for hepatitis B, 98.9% for hepatitis C) or had a blood test (90.9% for hepatitis B, 88.6% for hepatitis C) during the 10 years before HCC/DC diagnosis. The median number of GP visits was 24 and 32, and blood tests 7 and 8, for hepatitis B and C, respectively. Conclusions: Late diagnosis of viral hepatitis remains a concern, with the majority having frequent health‐care service provision in the preceding period, indicating missed opportunities for diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Associations between COVID‐19 and hospitalisation with respiratory and non‐respiratory conditions: a record linkage study.
- Author
-
Rowe, Stacey L, Leder, Karin, Dyson, Kylie, Sundaresan, Lalitha, Wollersheim, Dennis, Lynch, Brigid, Abdullahi, Ifrah, Cowie, Benjamin C, Stephens, Nicola, Nolan, Terence M, Sullivan, Sheena G, Sutton, Brett, and Cheng, Allen C
- Abstract
Objectives: To assess associations between SARS‐CoV‐2 infection and the incidence of hospitalisation with selected respiratory and non‐respiratory conditions in a largely SARS‐CoV‐2 vaccine‐naïve population. Design, setting, participants: Self‐control case series; analysis of population‐wide surveillance and administrative data for all laboratory‐confirmed COVID‐19 cases notified to the Victorian Department of Health (onset, 23 January 2020 – 31 May 2021; ie, prior to widespread vaccination rollout) and linked hospital admissions data (admission dates to 30 September 2021). Main outcome measures: Hospitalisation of people with acute COVID‐19; incidence rate ratios (IRRs) comparing incidence of hospitalisations with defined conditions (including cardiac, cerebrovascular, venous thrombo‐embolic, coagulative, and renal disorders) from three days before to within 89 days of onset of COVID‐19 with incidence during baseline period (60–365 days prior to COVID‐19 onset). Results: A total of 20 594 COVID‐19 cases were notified; 2992 people (14.5%) were hospitalised with COVID‐19. The incidence of hospitalisation within 89 days of onset of COVID‐19 was higher than during the baseline period for several conditions, including myocarditis and pericarditis (IRR, 14.8; 95% CI, 3.2–68.3), thrombocytopenia (IRR, 7.4; 95% CI, 4.4–12.5), pulmonary embolism (IRR, 6.4; 95% CI, 3.6–11.4), acute myocardial infarction (IRR, 3.9; 95% CI, 2.6–5.8), and cerebral infarction (IRR, 2.3; 95% CI, 1.4–3.9). Conclusion: SARS‐CoV‐2 infection is associated with higher incidence of hospitalisation with several respiratory and non‐respiratory conditions. Our findings reinforce the value of COVID‐19 mitigation measures such as vaccination, and awareness of these associations should assist the clinical management of people with histories of SARS‐CoV‐2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Women with hepatitis B: how mothers with chronic hepatitis B understand and experience the prevention of mother-to-child transmission interventions in Victoria, Australia.
- Author
-
Yussf, Nafisa, Wallace, Jack, Perrier, Meg, Romero, Nicole, Cowie, Benjamin, and Allard, Nicole
- Subjects
HEPATITIS B ,MATERNAL health services ,LIVER tumors ,PSYCHOLOGY of mothers ,PSYCHOLOGY of refugees ,RESEARCH methodology ,FEAR ,HEALTH status indicators ,COMMUNITY health services ,INTERVIEWING ,QUALITATIVE research ,SOUND recordings ,DESCRIPTIVE statistics ,RESEARCH funding ,HEPATITIS B vaccines ,THEMATIC analysis ,DATA analysis software ,CHRONIC hepatitis B ,VERTICAL transmission (Communicable diseases) ,MOTHER-child relationship - Abstract
Background: Mother-to-child transmission (MTCT) of hepatitis B can be prevented with targeted interventions; however, MTCT continues to occur in Australia and globally. This qualitative research investigated how mothers with chronic hepatitis B (CHB) understand and experience interventions for the prevention of MTCT of CHB (PMTCT-CHB) in Victoria, Australia. Methods: Semi-structured interviews were conducted with women with CHB. Participants were recruited through purposive and snowballing sampling. Interviews explored the women's experience of care for themselves and their infants aimed at PMTCT-CHB. Interviews were conducted over the phone with a qualified interpreter where required. The consolidated criteria for reporting qualitative research framework was used with data thematically analysed. This study was co-designed with mothers with CHB through a Community Advisory Group established for this research; coordinated and supported by LiverWELL and the researchers. Results: Sixteen women were interviewed. Although most women understood the purpose of hepatitis B vaccination, there were significant gaps in information and education provided to mothers regarding PMTCT-CHB. These gaps included understanding of the extent of protection of vaccination, breastfeeding with CHB, post-vaccination testing for infants and lack of clarity of the woman's own hepatitis B status. There was notable fear and worry associated with hepatitis B transmission, with emotional support for mothers identified as a major gap in service delivery. Additionally, some women experienced stigma and discrimination due to their hepatitis B and refugee status. Conclusions: This study explored how mothers with CHB understand and experience interventions to prevent MTCT. Our findings reveal substantial gaps in delivery of information and care in the context of PMTCT-CHB in Victoria. Our findings can support development of evidence-based interventions and systems to improve healthcare for mothers with CHB and their infants, and thereby reduce possible CHB transmission and other negative outcomes, including stigma and discrimination. This research investigated how mothers with chronic hepatitis B understand and experience interventions for the prevention of mother-to-child transmission of chronic hepatitis B in Victoria, Australia. It provides knowledge and insights in healthcare delivery gaps for pregnant women with hepatitis B and their infants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. COVID‐19 pandemic 2020: a tertiary Melbourne hospital's experience.
- Author
-
Farrow, Brodie, Bonney, Asha, Singh, Kasha P., Tong, Steven, Irving, Louis, Lim, Wen Kwang, Lim, Seok, Johnson, Douglas, Marshall, Caroline, Buising, Kirsty, Liu, Belinda, Cowie, Benjamin, Rees, Megan, and Miller, Alistair
- Subjects
WORK ,TERTIARY care ,ACQUISITION of data ,RETROSPECTIVE studies ,EXPERIENTIAL learning ,MEDICAL records ,COVID-19 pandemic ,LONGITUDINAL method - Abstract
Background: The COVID‐19 pandemic has affected different parts of Australia in distinct ways across 2020 and 2021. In 2020, Melbourne was the epicentre of COVID‐19. As one of the key tertiary centres caring for the patients affected by the outbreaks, the Royal Melbourne Hospital (RMH) managed the majority of the Victorian inpatient caseload. Aims: To review the demographics, management and outcomes of patients with COVID‐19 cared for by the RMH services in 2020. Methods: A single health service retrospective cohort analysis of demographics, interventions and outcomes was conducted to characterise the RMH experience in 2020. Results: From January to December 2020, 433 patients required admission more than 24 h. The demographics of affected patients and outcomes changed over the course of the study. Overall, 47% (203/433) required oxygen, most frequently (36%; 154/433) with low‐flow devices (nasal prongs or hudson mask), and 11% (47/433) of patients required admission to intensive care. We recorded a 30‐day mortality of 24% (104/433) mortality overall, rising to over 50% in patients aged over 80 years. Conclusions: The experience of this health service in 2020 demonstrated changing demographics over time, with associated differences in outcomes; notably marked mortality in older populations, frequent complications and limited inter‐site transfer possible with mobilised resources. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Australian consensus recommendations for the management of hepatitis B.
- Author
-
Lubel, John S, Strasser, Simone I, Thompson, Alexander J, Cowie, Benjamin C, MacLachlan, Jennifer, Allard, Nicole L, Holmes, Jacinta, Kemp, William W, Majumdar, Avik, Iser, David, Howell, Jess, and Matthews, Gail V
- Abstract
Introduction: The prevalence of hepatitis B virus (HBV) infection in Australia is nearly 1%. In certain well defined groups the prevalence is far greater, yet an estimated 27% of people living with HBV infection remain undiagnosed. Appropriate screening improves detection, increases opportunity for treatment, and ultimately reduces the significant morbidity and mortality associated with the development of liver fibrosis and hepatocellular carcinoma (HCC). Main recommendations: This statement highlights important aspects of HBV infection management in Australia. There have been recent changes in nomenclature and understanding of natural history, as well as a newly defined upper limit of normal for liver tests that determine phase classification and threshold for antiviral treatment. As the main burden of hepatitis B in Australia is within migrant and Indigenous communities, early identification and management of people living with hepatitis B is essential to prevent adverse outcomes including liver cancer and cirrhosis. Change in management as a result of this guideline: These recommendations aim to raise awareness of the current management of hepatitis B in Australia. Critically, the timely identification of individuals living with hepatitis B, and where appropriate, commencement of antiviral therapy, can prevent the development of cirrhosis, HCC and mother‐to‐child transmission as well as hepatitis B reactivation in immunocompromised individuals. Recognising patient and viral factors that predispose to the development of cirrhosis and HCC will enable clinicians to risk‐stratify and appropriately implement surveillance strategies to prevent these complications of hepatitis B. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. The COVID Positive Pathway: a collaboration between public health agencies, primary care, and metropolitan hospitals in Melbourne.
- Author
-
Lim, Seok Ming, Allard, Nicole L, Devereux, Janelle, Cowie, Benjamin C, Tydeman, Michelle, Miller, Alistair, Ho, Khanh, Cleveland, Brigitte, Singleton, Liz, Aarons, Karen, Eleftheriou, Paul, Chan, Thomas, Braitberg, George, and Maier, Andrea
- Abstract
Objectives: To assess the capacity of the COVID Positive Pathway, a collaborative model of care involving the Victorian public health unit, hospital services, primary care, community organisations, and the North Western Melbourne Primary Health Network, to support people with coronavirus disease 2019 (COVID‐19) isolating at home. Design, setting, participants: Cohort study of adults in northwest Melbourne with COVID‐19, 3 August ‒ 31 December 2020. Main outcome measures: Demographic and clinical characteristics, and social and welfare needs of people cared for in the Pathway, by care tier level. Results: Of 1392 people referred to the Pathway by the public health unit, 858 were eligible for enrolment, and 711 consented to participation; 647 (91%) remained in the Pathway until they had recovered and isolation was no longer required. A total of 575 participants (81%) received care in primary care, mostly from their usual general practitioners; 155 people (22%) received care from hospital outreach services, and 64 (9%) needed high tier care (hospitalisation). Assistance with food and other basic supplies was required by 239 people in the Pathway (34%). Conclusions: The COVID Positive Pathway is a feasible multidisciplinary, tiered model of care for people with COVID‐19. About 80% of participants could be adequately supported by primary care and community organisations, allowing hospital services to be reserved for people with more severe illness or with risk factors for disease progression. The principles of this model could be applied to other health conditions if regulatory and funding barriers to information‐sharing and care delivery by health care providers can be overcome. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Financing viral hepatitis: catalysing action for impact
- Author
-
Hicks, Jessica, Singh, Grace, Penicaud, Capucine, Gustafson, Kiira, James, Cary, Burke-Shyne, Naomi, Daniels, Colleen, Fernandes, Oriel, Green, Kimberly E, Cowie, Benjamin, Ward, John W, Roberts, Teri, and Ruiz Villafranca, David
- Published
- 2023
- Full Text
- View/download PDF
21. Performance of hospital-based contact tracing for COVID-19 during Australia's second wave.
- Author
-
Bailie, Christopher R., Leung, Vivian K., Orr, Elizabeth, Singleton, Elizabeth, Kelly, Cate, Buising, Kirsty L., Cowie, Benjamin C., Kirk, Martyn D., Sullivan, Sheena G., and Marshall, Caroline
- Published
- 2022
- Full Text
- View/download PDF
22. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia.
- Author
-
Toy, Mehlika, Hutton, David, McCulloch, Karen, Romero, Nicole, Revill, Peter A., Penicaud, M‐Capucine, So, Samuel, Cowie, Benjamin C., and Lampertico, Pietro
- Subjects
CHRONIC hepatitis B ,COST analysis ,PRICE marks ,HEPATITIS B ,VIRUS diseases - Abstract
Background & Aims: We aim to capture the economic impact of a potential cure for chronic hepatitis B infection (CHB) in three countries (USA, China and Australia) with different health systems and epidemics to estimate the threshold drug prices below which a CHB cure would be cost‐saving and/or highly cost‐effective. Methods: We simulated patients' hepatitis B progression, under three scenarios: current long‐term suppressive antiviral therapy, functional cure defined as sustained undetectable HBsAg and HBV DNA, and partial cure defined as sustained undetectable HBV DNA only after a finite, 48‐week treatment. Results: Compared with current long‐term antiviral therapy, a 30% effective functional cure among patients with and without cirrhosis in the USA, China and Australia would yield 17.50, 17.32 and 20.42 QALYs per patient, and 20.61, 20.42 and 20.62 QALYs per patient respectively. In financial terms, for CHB patients with and without cirrhosis, this would be cost‐saving at a one‐time treatment cost under US$11 944 and US$6694, respectively, in the USA, US$1744 and US$1001 in China, and US$12 063 and US$10 983 in Australia. Conclusion: We show that in purely economic terms, a CHB cure will be highly cost‐effective even if effective in only 30% of treated patients. The threshold price for cure is largely determined by the current antiviral drug costs, since it will replace a daily antiviral pill that is inexpensive and effective, although not curative. The likely need for combination therapies to achieve cure will also present cost challenges. While cost‐effectiveness is important, it cannot be the only consideration, as cure will provide many benefits in addition to reduced liver disease and HCC, including eliminating the need for a long‐term daily pill and reducing stigma often associated with chronic viral infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Universal testing for hepatitis B must be accompanied by better linkage with care.
- Author
-
Tran, Lien and Cowie, Benjamin C
- Abstract
The latter parameter has substantial influence on the question of whether a universal testing approach is likely to be cost-effective.[8] Testing alone cannot achieve the desired individual or public health outcomes; what happens after a positive test result determines the benefits realised. Keywords: Hepatitis B; Public policy; Mass screening EN Hepatitis B Public policy Mass screening 165 166 2 03/08/23 20230301 NES 230301 Comprehensive testing, monitoring, and treatment in primary care could save hundreds of Australian lives each year Tens of thousands of Australians have undiagnosed chronic hepatitis B, most since infancy.[1] Chronic hepatitis B is an important cause of cirrhosis, liver failure, and hepatocellular carcinoma. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
24. A hospital-wide response to multiple outbreaks of COVID-19 in health care workers: Lessons learned from the field.
- Author
-
Marshall, Caroline, Buising, Kirsty, Williamson, Deborah, Cowie, Benjamin, MacLachlan, Jennifer, Orr, Elizabeth, MacIsaac, Christopher, Williams, Eloise, Bond, Katherine, Muhi, Stephen, McCarthy, James, Maier, Andrea, Irving, Louis, Heinjus, Denise, and Kelly, Cate
- Published
- 2021
- Full Text
- View/download PDF
25. Paxlovid is Australia's first-line COVID antiviral but Lagevrio also prevents severe disease in over-70s.
- Author
-
Cowie, Benjamin, Sutton, Brett, Van Heer, Christina, and Majumdar, Suman
- Subjects
COVID-19 treatment ,COVID-19 - Abstract
Read more: COVID drugs in Australia: what's available and howto get them Some important limitations of this analysis are that it'sobservational, so we can't control for a number of factorsassociated with hospitalisation and death from COVID. Australia is experiencing the fourth wave of COVID for 2022,with the number of people hospitalised with COVID trending tolevels seen in winter and ongoing high levels of deaths. [Extracted from the article]
- Published
- 2022
26. Hepatitis B clinical care provision in pregnancy: A whole‐of‐population linkage study in Victoria, Australia.
- Author
-
MacLachlan, Jennifer H, Romero, Nicole, Allard, Nicole, Rowe, Stacey L, and Cowie, Benjamin C
- Subjects
- *
CHRONIC hepatitis B , *GENERAL practitioners , *VIRAL load , *CLINICAL medicine , *HEPATITIS B - Abstract
Background and Aim Methods Results Conclusions Pregnancy is a key setting for engagement in chronic hepatitis B (CHB) care, due to the implications for transmission to the infant and antenatal diagnosis representing an opportunity for ongoing follow‐up. This study aimed to identify the coverage and predictors of clinical care for women with CHB during and after pregnancy in a population‐level cohort.Notified CHB cases in Victoria, Australia, were linked with hospitalizations, medical services, and prescribing data, covering the period 1991–2018. Women with an admission for a live birth were identified and services provided during pregnancy were assessed, including general practitioner (GP) or specialist visits, viral load and serology testing, and antiviral treatment. Viral load and serology testing coverage ware also assessed for the 2‐year period following pregnancy. Demographic and clinical predictors of viral load testing during pregnancy were assessed.A total of 11 015 birth events occurred for 6090 women with CHB. During pregnancy most had a GP consultation (91.6%); however, only 39.5% had viral load testing and 41.4% had a gastroenterology or infectious diseases specialist consultation. Viral load testing and serology testing in the 2 years after pregnancy occurred in approximately half (47.9% and 52.2%, respectively) with increases over time. Viral load testing was more likely in those born overseas, those with more than one previous birth, and those living in Melbourne.Despite improvements over time, key gaps were identified in the provision of CHB clinical care during and after pregnancy, with implications for ongoing transmission and adverse outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Uptake of perinatal immunoprophylaxis for infants born to women with a record of hepatitis B in Victoria (2009–2017).
- Author
-
Deng, Hui Min-Anna, Romero, Nicole, Allard, Nicole, Rowe, Stacey, Yussf, Nafisa, and Cowie, Benjamin
- Subjects
- *
HEPATITIS B , *CHRONIC hepatitis B , *INFANTS , *HEPATITIS B vaccines , *HEPATITIS B virus - Abstract
• Between 2009 and 2017, 6118 births (0.90%) were linked to 4196 women with CHB. • Birth dose was recorded for 89.4 % of all Victorian infants within 7 days. • 96.8 % of infants linked to women with CHB received birth dose within 7 days. • 2.3% of infants linked to women with CHB, had a record of HBIG administration. Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) remains one of the leading causes of transmission worldwide. An estimated 90 % of infants who are exposed to HBV and do not receive appropriate post exposure immunoprophylaxis will go on to develop chronic hepatitis B (CHB). In Australia, universal birth dose vaccination was adopted in 2000 and universal antenatal screening for hepatitis B was introduced in the 1990 s, however up to 10 % of women may have missed screening. There is no coordinated care or data collection that systematically reports the access to interventions to prevent mother-to-child transmission (PMTCT) for women with CHB. Therefore, the incidence rate of MTCT is unknown. We conducted retrospective data linkage of perinatal records, public health notification and hospital admission data to identify women with a record of HBV infection who had given birth to a live infant(s) in Victoria between 2009 and 2017. We assessed uptake of birth dose vaccination and hepatitis B immunoglobulin (HBIG) and explored factors associated with administration of birth dose recorded as administered within 7 days. Among 690,052 live births, 6118 births (0.90 %) were linked to 4196 women with a record of HBV infection. 89.4 % of all Victorian infants (n = 616,879), and 96.8 % of infants linked to women with a positive record of CHB (n = 5,925) received birth dose within 7 days. Infants born in private hospitals had reduced odds of receiving birth dose when compared to public hospitals births (Victorian population, aOR = 0.67, 95 %CI = 0.66, 0.69; CHB linked records aOR = 0.17, 95 %CI = 0.11, 0.25). Of the 6118 infants linked to a positive maternal record of CHB, discrepant recording of maternal CHB status between the three datasets was identified in 72.4% of records and HBIG administration was recorded for only 2.3% of births. An approach that involves coordinated care and integrates data collection for women with CHB and their infants is required to support the elimination of MTCT of hepatitis B in Victoria. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. A pilot project harnessing surveillance systems to support clinicians providing clinical care for people diagnosed with hepatitis C in Victoria, Australia, September 2021 to 31 March 2022.
- Author
-
Abbott M, MacLachlan JH, Romero N, Matthews N, Higgins N, Lee A, Stoove M, Marukutira T, Quinn B, Allard NL, and Cowie BC
- Subjects
- Humans, Pilot Projects, Male, Female, Middle Aged, Adult, Victoria, Disease Notification, Aged, Hepacivirus isolation & purification, Hepacivirus genetics, Population Surveillance methods, Contact Tracing methods, Hepatitis C, Chronic diagnosis, Hepatitis C diagnosis
- Abstract
BackgroundActive follow-up of chronic hepatitis C notifications to promote linkage to care is a promising strategy to support elimination.AimThis pilot study in Victoria, Australia, explored if the Department of Health could follow-up on hepatitis C cases through their diagnosing clinicians, to assess and support linkage to care and complete data missing from the notification.MethodsFor notifications received between 1 September 2021 and 31 March 2022 of unspecified hepatitis C cases (i.e. acquired > 24 months ago or of unknown duration), contact with diagnosing clinicians was attempted. Data were collected on risk exposures, clinical and demographic characteristics and follow-up care (i.e. HCV RNA test; referral or ascertainment of previous negative testing or treatment history). Reasons for unsuccessful doctor contact and gaps in care provision were investigated. Advice to clinicians on care and resources for clinical support were given on demand.ResultsOf 513 cases where information was sought, this was able to be obtained for 356 (69.4%). Reasons for unsuccessful contact included incomplete contact details or difficulties getting in touch across three attempts, particularly for hospital diagnoses. Among the 356 cases, 307 (86.2%) had received follow-up care. Patient-management resources were requested by 100 of 286 contacted diagnosing clinicians.ConclusionsMost doctors successfully contacted had provided follow-up care. Missing contact information and the time taken to reach clinicians significantly impeded the feasibility of the intervention. Enhancing system automation, such as integration of laboratory results, could improve completeness of notifications and support further linkage to care where needed.
- Published
- 2024
- Full Text
- View/download PDF
29. Australian vaccine preventable disease epidemiological review series: Hepatitis B, 2000-2019.
- Author
-
Sonneveld N, Jackson J, Dey A, Lambert SB, Clark KK, Cowie BC, Macartney K, and Beard F
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Young Adult, Australia epidemiology, Disease Notification statistics & numerical data, Hospitalization statistics & numerical data, Immunization Programs, Vaccination statistics & numerical data, Australian Aboriginal and Torres Strait Islander Peoples, Hepatitis B epidemiology, Hepatitis B prevention & control, Hepatitis B Vaccines administration & dosage
- Abstract
Introduction: Hepatitis B vaccination was nationally funded for adolescents in 1996, with inclusion of universal infant immunisation under the National Immunisation Program (NIP) in May 2000. This study describes hepatitis B epidemiology in Australia in the two decades since 2000., Methods: This article analyses newly-acquired (within the prior 24 months) and unspecified (all other) hepatitis B notifications (2000-2019) from the National Notifiable Diseases Surveillance System; acute hepatitis B hospitalisations (2001-2019) from the National Hospital Morbidity Database; and acute (2000-2019) and chronic (2006-2019) hepatitis B deaths from the Australian Bureau of Statistics and Australian Coordinating Registry. Rates over the reporting period were described overall, and by age group, sex, and Aboriginal and Torres Strait Islander status (Aboriginal and/or Torres Strait Islander versus other [neither Aboriginal nor Torres Strait Islander, unknown or not stated]). Trend analyses were performed using Poisson or negative binomial regression. Additional analyses were performed for the cohort born after May 2000., Results and Discussion: The annual all-age notification rate per 100,000 per year declined (p < 0.001) from 2.13 in 2000 to 0.65 in 2019 for newly-acquired hepatitis B and from 38.3 to 22.3 for unspecified hepatitis B (likely to predominantly represent chronic hepatitis B). Newly-acquired and unspecified hepatitis B notification rates were lowest among children aged < 15 years. The most substantial reductions in notification rates of newly-acquired hepatitis B were among adolescents aged 15-19 years and young adults aged 20-24 and 25-29 years (respectively 17-, 11-, and 7-fold); these age groups also recorded the most substantial reductions in unspecified hepatitis B notifications (respectively 5-, 3.5-, and 2-fold). Newly-acquired hepatitis B notification and acute hepatitis B mortality rates were two- to threefold higher in males than females. The all-age newly-acquired hepatitis B notification rate in Aboriginal and Torres Strait Islander people decreased twofold between 2000 and 2019, but remained threefold higher than in other people. Acute hepatitis B hospitalisations also declined over the study period (p < 0.001) and followed similar patterns. There were no acute or chronic hepatitis B deaths among people born after May 2000; this cohort featured 52 newly-acquired and 887 unspecified hepatitis B notifications. Due to lack of data on country of birth (and hence eligibility for infant vaccination under the NIP or overseas programs), vaccination status and likely transmission routes, we were unable to assess factors contributing to these potentially preventable infections., Conclusion: Adolescent and infant immunisation under the NIP has led to significant reductions in notification rates of newly-acquired hepatitis B, and in acute hepatitis B hospitalisation rates, both overall and in Aboriginal and Torres Strait Islander people. Unspecified hepatitis B notification rates have also greatly decreased in children and young adults, likely largely due to the impact of overseas infant immunisation programs on prevalence in child and adolescent migrants. Work to improve completeness of variables within national datasets is crucial, along with enhanced surveillance of both newly-acquired and unspecified hepatitis B cases to investigate transmission routes, vaccination status and factors contributing to acquisition of hepatitis B, in order to optimise the impact of immunisation programs and ensure linkage with care., (© Commonwealth of Australia CC BY-NC-ND.)
- Published
- 2024
- Full Text
- View/download PDF
30. Exploring the Public Health and Social Implications of Future Curative Hepatitis B Interventions.
- Author
-
Wallace J, Richmond J, Howell J, Hajarizadeh B, Power J, Treloar C, Revill PA, Cowie B, Wang S, Stoové M, Pedrana A, and Hellard M
- Subjects
- Humans, Public Health, Hepacivirus, Hepatitis B epidemiology, Hepatitis B prevention & control, Hepatitis C, Hepatitis, Viral, Human
- Abstract
Hepatitis B is a significant global health issue where the 296 million people estimated to live with the infection risk liver disease or cancer without clinical intervention. The World Health Organization has committed to eliminating viral hepatitis as a public health threat by 2030, with future curative hepatitis B interventions potentially revolutionizing public health responses to hepatitis B, and being essential for viral hepatitis elimination. Understanding the social and public health implications of any cure is imperative for its successful implementation. This exploratory research, using semi-structured qualitative interviews with a broad range of professional stakeholders identifies the public health elements needed to ensure that a hepatitis B cure can be accessed by all people with hepatitis B. Issues highlighted by the experience of hepatitis C cure access include preparatory work to reorientate policy settings, develop resourcing options, and the appropriateness of health service delivery models. While the form and complexity of curative hepatitis B interventions are to be determined, addressing current disparities in cascade of care figures is imperative with implementation models needing to respond to the cultural contexts, social implications, and health needs of people with hepatitis B, with cure endpoints and discourse being contested.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.